Henry Schein (NASDAQ:HSIC) Releases FY 2026 Earnings Guidance

Henry Schein (NASDAQ:HSIC) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 5.230-5.370 for the period, compared to the consensus EPS estimate of 5.280. The company issued revenue guidance of $13.6 billion-$13.8 billion, compared to the consensus revenue estimate of $13.5 billion.

Henry Schein Stock Up 1.3%

Shares of NASDAQ:HSIC opened at $80.57 on Tuesday. The company’s fifty day moving average is $77.43 and its 200-day moving average is $71.78. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40. Henry Schein has a 52 week low of $60.56 and a 52 week high of $82.80. The company has a market capitalization of $9.49 billion, a PE ratio of 25.50, a P/E/G ratio of 2.37 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities research analysts predict that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on HSIC shares. JPMorgan Chase & Co. lifted their target price on shares of Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Robert W. Baird set a $100.00 price objective on Henry Schein and gave the company an “outperform” rating in a research report on Monday. Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Barclays began coverage on Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price for the company. Finally, Barrington Research set a $79.00 price target on Henry Schein and gave the company an “outperform” rating in a report on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Henry Schein presently has an average rating of “Hold” and an average price target of $78.75.

Hedge Funds Weigh In On Henry Schein

Hedge funds have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. increased its position in Henry Schein by 3,275.2% in the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after purchasing an additional 2,199,695 shares during the period. Bank of Montreal Can boosted its stake in shares of Henry Schein by 3,655.7% in the 4th quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after purchasing an additional 2,087,666 shares during the last quarter. Southpoint Capital Advisors LP grew its position in shares of Henry Schein by 38.9% during the 4th quarter. Southpoint Capital Advisors LP now owns 2,500,000 shares of the company’s stock worth $188,950,000 after buying an additional 700,000 shares during the period. Bank of America Corp DE grew its position in shares of Henry Schein by 204.2% during the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after buying an additional 668,182 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Henry Schein by 8.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,816,317 shares of the company’s stock worth $212,865,000 after buying an additional 220,149 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.